Kainova Therapeutics to Present Clinical and Preclinical Updates on its GPCR Programs at AACR Annual Meeting 2026
- Phase I / II DOMISOL study design for DT-7012, a Treg-depleting anti-CCR8 antibody
- Comprehensive preclinical characterization of DT-7012, highlighting its differentiated binding and effector-function properties
- Biomarker analyses from the completed Phase I EPRAD study of DT-9081, an EP4 receptor antagonist
Montreal, Canada – Strasbourg, France – Boston, United States, March 26, 2026: Kainova Therapeutics ( “the Company” ), a key player for breakthrough treatments in immuno-oncology and inflammation, today announced that it will present clinical and preclinical updates from its oncology pipeline at the American Association for Cancer Research ( AACR ) Annual Meeting 2026, taking place April 17-22 in San Diego, California.
The presentations reflect the breadth of the Company’s GPCR-modulating programs, from preclinical mechanism of action studies to clinical trial design and translational biomarker evaluation.
Poster Presentation Details:
Poster Title: Comprehensive characterization of DT-7012, a highly differentiated anti-CCR8 depleting antibody
Session: Monoclonal Antibodies and Antibody-Cytokine Platforms
Date & Time: April 21, 2026, 9:00 AM -12:00 PM PST
Location: Poster Section 9
Poster Board Number: 27
Abstract Presentation Number: 4356
DT-7012 is a Phase I / II differentiated anti-CCR8 monoclonal antibody candidate designed to selectively deplete highly immunosuppressive regulatory T cells ( Tregs ). This poster will describe the preclinical characterization of DT-7012, including its unique CCR8 binding profile, effector-function potency, and selectivity compared with other clinical-stage CCR8-targeting antibodies.
Poster Title: Design and rationale of DOMISOL, a first-in-human Phase I / II study of
DT-7012 ( NCT06819735 ) in advanced solid tumors
Session: Phase I and Phase II Clinical Trials in Progress
Date & Time: April 21, 2026, 2:00-5:00 PM PST
Location: Poster Section 51
Poster Board Number: 19
Abstract Presentation Number: CT285
This poster will outline the design and scientific rationale of DOMISOL, the ongoing first-in-human, multicenter, open-label Phase I/II trial evaluating safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of DT-7012 in patients with advanced solid tumors.
Poster Title: Biomarker dynamics in the completed Phase I study of DT-9081: An analysis of ex vivo cytokine stimulation, urinary PGEM, and tumoral biomarkers in advanced solid tumors
Session: Biomarkers Predictive of Therapeutics Benefit 5
Date & Time: April 21, 2026, 9:00 AM -12:00 PM PST
Location: Poster Section 42
Poster Board Number: 5
Abstract Presentation Number: 5239
This poster will present integrated biomarker analyses from the completed Phase I EPRAD study of DT-9081, an oral EP4 receptor antagonist, including ex vivo cytokine stimulation, urinary PGEM, tumor-based biomarkers, and plasma cytokine dynamics.
Stephan Schann, Chief Scientific Officer of Kainova Therapeutics said: “We look forward to sharing these insights with the scientific community at AACR, as they reflect the scientific foundation of our GPCR-modulating programs and the thoughtful approach guiding their advancement. These learnings across preclinical, translational, and clinical contexts are essential to understanding where GPCR modulation may meaningfully shape therapeutic development.”
ENDS
For more information, please contact:
Optimum Strategic Communications
Mary Clark, Zoe Bolt, Elena Bates, Nellie Stephens
+44 (0) 203 882 9621
kainova@optimumcomms.com
For French media:
communication@kainovatx.com